表紙:乳癌治療薬の世界市場 (2022-2028年):市場予測 (療法別)・地域的展望・用途の成長の潜在性・COVID-19の影響・市場シェア
市場調査レポート
商品コード
1062834

乳癌治療薬の世界市場 (2022-2028年):市場予測 (療法別)・地域的展望・用途の成長の潜在性・COVID-19の影響・市場シェア

Breast Cancer Therapeutics Market Size By Therapy, Industry Analysis Report, Regional Outlook, Application Development Potential, Covid-19 Impact Analysis, Competitive Market Share & Forecast, 2022 - 2028

出版日: | 発行: Global Market Insights Inc. | ページ情報: 英文 90 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=135.61円
乳癌治療薬の世界市場 (2022-2028年):市場予測 (療法別)・地域的展望・用途の成長の潜在性・COVID-19の影響・市場シェア
出版日: 2022年02月15日
発行: Global Market Insights Inc.
ページ情報: 英文 90 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

乳癌治療薬の市場シェアは、世界中で乳癌患者が急増していることから、2028年にかけて急拡大すると予測されています。

さらに、ラテンアメリカなどの低・中所得地域における有病率の増加も今後数年の市場を大きく推進すると予測されています。

化学療法の部門は2028年に40億米ドル超の規模へと大きく成長すると予測されています。これは主に、化学療法に対する患者の嗜好の高さや、新製品の上市などによるものです。また、免疫療法も大きな成長が見込まれています。乳癌は免疫学的に「冷たい」癌であるため、以前は免疫療法による治療が困難とされていましたが、最近の臨床研究や新薬の発見により、免疫療法は多くの乳癌患者の治療成績を向上させる可能性を持っていることが明らかになっています。

当レポートでは、世界の乳癌治療薬の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制・償還環境、パイプラインの動向、市場規模の推移・予測、療法・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

第3章 乳癌治療薬産業の考察

  • 産業の分類
  • 産業情勢
  • 産業の影響因子
    • 成長要因
    • 潜在的リスク&課題
  • 成長の可能性
  • COVID-19:影響分析
  • 規制状況
  • 償還シナリオ
  • パイプライン分析
  • ポーターの分析
  • 競合情勢
  • PESTEL分析

第4章 乳癌治療薬市場:療法別

  • 主要動向
  • 標的療法
  • ホルモン療法
  • 化学療法
  • 免疫療法

第5章 乳癌治療薬市場:地域別

  • 主要動向
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第6章 企業プロファイル

  • 競合ダッシュボード
  • AstraZeneca plc
  • Eli Lilly & Co, Inc.
  • Pfizer, Inc.
  • Bristol Myers Squibb
  • Novartis AG
  • Amgen
  • F. Hoffmann La Roche AG
  • Merck & Co, Inc.
  • Sanofi
  • Eisai Co., Ltd.
図表

Data Tables

  • TABLE 1. Breast cancer therapeutics industry 360 degree synopsis, 2017-2028
  • TABLE 2. Global breast cancer therapeutics market, 2017 - 2021 (USD Million)
  • TABLE 3. Global breast cancer therapeutics market, 2022 - 2028 (USD Million)
  • TABLE 4. Global breast cancer therapeutics market, by therapy, 2017 - 2021 (USD Million)
  • TABLE 5. Global breast cancer therapeutics market, by therapy, 2022 - 2028 (USD Million)
  • TABLE 6. Global breast cancer therapeutics market, by region, 2017 - 2021 (USD Million)
  • TABLE 7. Global breast cancer therapeutics market, by region, 2022 - 2028 (USD Million)
  • TABLE 8. Industry impact forces
  • TABLE 9. Targeted therapy market size, by region, 2017 - 2021 (USD Million)
  • TABLE 10. Targeted therapy market size, by region, 2022 - 2028 (USD Million)
  • TABLE 11. Hormonal therapy market size, by region, 2017 - 2021 (USD Million)
  • TABLE 12. Hormonal therapy market size, by region, 2022 - 2028 (USD Million)
  • TABLE 13. Chemotherapy market size, by region, 2017 - 2021 (USD Million)
  • TABLE 14. Chemotherapy market size, by region, 2022 - 2028 (USD Million)
  • TABLE 15. Immunotherapy market size, by region, 2017 - 2021 (USD Million)
  • TABLE 16. Immunotherapy market size, by region, 2022 - 2028 (USD Million)
  • TABLE 17. North America breast cancer therapeutics market size, by country, 2017 - 2021 (USD Million)
  • TABLE 18. North America breast cancer therapeutics market size, by country, 2022 - 2028 (USD Million)
  • TABLE 19. North America breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 20. North America breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 21. U.S. breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 22. U.S. breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 23. Canada breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 24. Canada breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 25. Europe breast cancer therapeutics market size, by country, 2017 - 2021 (USD Million)
  • TABLE 26. Europe breast cancer therapeutics market size, by country, 2022 - 2028 (USD Million)
  • TABLE 27. Europe breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 28. Europe breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 29. Germany breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 30. Germany breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 31. UK breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 32. UK breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 33. France breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 34. France breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 35. Italy breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 36. Italy breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 37. Spain breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 38. Spain breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 39. Asia Pacific breast cancer therapeutics market size, by country, 2017 - 2021 (USD Million)
  • TABLE 40. Asia Pacific breast cancer therapeutics market size, by country, 2022 - 2028 (USD Million)
  • TABLE 41. Asia Pacific breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 42. Asia Pacific breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 43. China breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 44. China breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 45. India breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 46. India breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 47. Japan breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 48. Japan breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 49. Australia breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 50. Australia breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 51. South Korea breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 52. South Korea breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 53. Latin America breast cancer therapeutics market size, by country, 2017 - 2021 (USD Million)
  • TABLE 54. Latin America breast cancer therapeutics market size, by country, 2022 - 2028 (USD Million)
  • TABLE 55. Latin America breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 56. Latin America breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 57. Brazil breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 58. Brazil breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 59. Mexico breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 60. Mexico breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 61. Argentina breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 62. Argentina breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 63. MEA breast cancer therapeutics market size, by country, 2017 - 2021 (USD Million)
  • TABLE 64. MEA breast cancer therapeutics market size, by country, 2022 - 2028 (USD Million)
  • TABLE 65. MEA breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 66. MEA breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 67. South Africa breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 68. South Africa breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 69. Saudi Arabia breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 70. Saudi Arabia breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)
  • TABLE 71. UAE breast cancer therapeutics market size, by therapy, 2017 - 2021 (USD Million)
  • TABLE 72. UAE breast cancer therapeutics market size, by therapy, 2022 - 2028 (USD Million)

Charts & Figures

  • FIG. 1 Top-down approach (supply side analysis)
  • FIG. 2 Industry segmentation
  • FIG. 3 Global breast cancer therapeutics market size, 2017 - 2028 (USD Million)
  • FIG. 4 Growth potential analysis, by therapy
  • FIG. 5 Porter's analysis
  • FIG. 6 Competitive matrix analysis
  • FIG. 7 PESTEL analysis
  • FIG. 8 Key segment trends, by therapy
  • FIG. 9 Key regional trends
  • FIG. 10 Competitive dashboard, 2021
目次
Product Code: 466

The breast cancer therapeutics market share is projected to grow rapidly by 2028 on account of the rapidly growing cases of breast cancer around the globe. Additionally, growing prevalence of the disease in low-to middle-income regions, such as Latin America, is also pegged to be a prominent driving factor for the market in coming years.

Last year, the WHO stated that the latest statistics released by the IARC (International Agency for Research on Cancer), now classifies breast cancer as the most common type of cancer in the world. The disease overtook lung cancer to take this number one spot.

Contrary to the general notion, breast cancer does not just affect women but can also occur in men, although the chances of it occurring in women is far higher than in men. According to the Cancer Research Institute, about 1 in 8 women and approximately 1 in 1000 men will, at some point in their lives, develop invasive breast cancer.

The coronavirus pandemic has severely exacerbated the challenges of late-stage cancer diagnosis and lack of adequate access to treatment. While this issue has emerged everywhere, they are particularly widespread in low- and middle-income nations. A 2020 WHO survey has reported that cancer treatment was moderately-to-severely disrupted in over 40% of nations surveyed at the peak of the pandemic.

However, with successful vaccination drives bringing back hospital capacities to their pre-pandemic levels, the cancer therapeutics market is slated to witness an economic bounce back at a notable pace.

The overall breast cancer therapeutics market is categorized into two segments of product, and regional landscape.

The product segment is further branched off into hormonal therapy, targeted therapy, immunotherapy, and chemotherapy. Among these, the chemotherapy segment is forecast to witness substantial growth, wherein it will reach a valuation of more than USD 4.0 billion by 2028. This would mainly be owing to the significant patient preference for chemotherapy, and new product launches among others.

The immunotherapy segment is also earmarked for strong growth. While breast cancer was previously regarded as 'difficult to treat' through immunotherapy, owing to it being immunologically 'cold', recent clinical studies and novel drug discoveries have showcased that immunotherapy treatment possesses the potential to enhance the outcomes for many breast cancer patients.

From a regional reference frame, the Middle East & Africa breast cancer therapeutics market is expected to showcase notable growth. The segment was valued at over USD 631 million back in 2021, and is projected to witness significant growth due to high incidence of breast cancer across various countries in the region.

Table of Contents

Chapter 1 Methodology

  • 1.1 Market definition
  • 1.2 Base estimates & working
  • 1.3 Forecast parameters
  • 1.4 Data validation
  • 1.5 Data sources
    • 1.5.1 Secondary
      • 1.5.1.1 Paid sources
      • 1.5.1.2 Unpaid sources
    • 1.5.2 Primary

Chapter 2 Executive Summary

  • 2.1 Breast cancer therapeutics industry 360 degree synopsis, 2017 - 2028
    • 2.1.1 Business trends
    • 2.1.2 Therapy trends
    • 2.1.3 Regional trends

Chapter 3 Breast Cancer Therapeutics Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2017 - 2028 (USD Million)
  • 3.3 Industry impact factors
    • 3.3.1 Growth drivers
      • 3.3.1.1 Growing burden of breast cancer
      • 3.3.1.2 Advancements in cancer biology and pharmacology promoting drug development
      • 3.3.1.3 Increasing investments in R&D
      • 3.3.1.4 Launch of several diagnostic and screening programs
      • 3.3.1.5 Favourable insurance and reimbursement policies
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 Side-effects associated with breast cancer drugs
      • 3.3.2.2 High cost of drugs
  • 3.4 Growth potential analysis
    • 3.4.1 By therapy
  • 3.5 COVID-19 impact analysis
  • 3.6 Regulatory landscape
    • 3.6.1 U.S.
    • 3.6.2 Europe
  • 3.7 Reimbursement scenario
  • 3.8 Pipeline analysis
  • 3.9 Porter's analysis
  • 3.10 Competitive landscape, 2021
    • 3.10.1 Company matrix analysis, 2021
  • 3.11 PESTEL analysis

Chapter 4 Breast Cancer Therapeutics Market, By Therapy

  • 4.1 Key segment trends
  • 4.2 Targeted therapy
    • 4.2.1 Market size, by region, 2017 - 2028 (USD Million)
  • 4.3 Hormonal therapy
    • 4.3.1 Market size, by region, 2017 - 2028 (USD Million)
  • 4.4 Chemotherapy
    • 4.4.1 Market size, by region, 2017 - 2028 (USD Million)
  • 4.5 Immunotherapy
    • 4.5.1 Market size, by region, 2017 - 2028 (USD Million)

Chapter 5 Breast Cancer Therapeutics Market, By Region

  • 5.1 Key regional trends
  • 5.2 North America
    • 5.2.1 Market size, by country, 2017 - 2028 (USD Million)
    • 5.2.2 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.2.3 U.S.
      • 5.2.3.1 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.2.4 Canada
      • 5.2.4.1 Market size, by therapy, 2017 - 2028 (USD Million)
  • 5.3 Europe
    • 5.3.1 Market size, by country, 2017 - 2028 (USD Million)
    • 5.3.2 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.3.3 Germany
      • 5.3.3.1 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.3.4 UK
      • 5.3.4.1 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.3.5 France
      • 5.3.5.1 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.3.6 Italy
      • 5.3.6.1 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.3.7 Spain
      • 5.3.7.1 Market size, by therapy, 2017 - 2028 (USD Million)
  • 5.4 Asia Pacific
    • 5.4.1 Market size, by country, 2017 - 2028 (USD Million)
    • 5.4.2 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.4.3 China
      • 5.4.3.1 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.4.4 India
      • 5.4.4.1 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.4.5 Japan
      • 5.4.5.1 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.4.6 Australia
      • 5.4.6.1 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.4.7 South Korea
      • 5.4.7.1 Market size, by therapy, 2017 - 2028 (USD Million)
  • 5.5 Latin America
    • 5.5.1 Market size, by country, 2017 - 2028 (USD Million)
    • 5.5.2 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.5.3 Brazil
      • 5.5.3.1 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.5.4 Mexico
      • 5.5.4.1 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.5.5 Argentina
      • 5.5.5.1 Market size, by therapy, 2017 - 2028 (USD Million)
  • 5.6 Middle East and Africa
    • 5.6.1 Market size, by country, 2017 - 2028 (USD Million)
    • 5.6.2 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.6.3 South Africa
      • 5.6.3.1 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.6.4 Saudi Arabia
      • 5.6.4.1 Market size, by therapy, 2017 - 2028 (USD Million)
    • 5.6.5 UAE
      • 5.6.5.1 Market size, by therapy, 2017 - 2028 (USD Million)

Chapter 6 Company Profiles

  • 6.1 Competitive dashboard, 2021
  • 6.2 AstraZeneca plc
    • 6.2.1 Business overview
    • 6.2.2 Financial data
    • 6.2.3 Therapy landscape
    • 6.2.4 Strategic outlook
    • 6.2.5 SWOT analysis
  • 6.3 Eli Lilly & Co, Inc.
    • 6.3.1 Business overview
    • 6.3.2 Financial data
    • 6.3.3 Therapy landscape
    • 6.3.4 Strategic outlook
    • 6.3.5 SWOT analysis
  • 6.4 Pfizer, Inc.
    • 6.4.1 Business overview
    • 6.4.2 Financial data
    • 6.4.3 Therapy landscape
    • 6.4.4 Strategic outlook
    • 6.4.5 SWOT analysis
  • 6.5 Bristol Myers Squibb
    • 6.5.1 Business overview
    • 6.5.2 Financial data
    • 6.5.3 Therapy landscape
    • 6.5.4 Strategic outlook
    • 6.5.5 SWOT analysis
  • 6.6 Novartis AG
    • 6.6.1 Business overview
    • 6.6.2 Financial data
    • 6.6.3 Therapy landscape
    • 6.6.4 Strategic outlook
    • 6.6.5 SWOT analysis
  • 6.7 Amgen
    • 6.7.1 Business overview
    • 6.7.2 Financial data
    • 6.7.3 Therapy landscape
    • 6.7.4 Strategic outlook
    • 6.7.5 SWOT analysis
  • 6.8 F. Hoffmann La Roche AG
    • 6.8.1 Business overview
    • 6.8.2 Financial data
    • 6.8.3 Therapy landscape
    • 6.8.4 Strategic outlook
    • 6.8.5 SWOT analysis
  • 6.9 Merck & Co, Inc.
    • 6.9.1 Business overview
    • 6.9.2 Financial data
    • 6.9.3 Therapy landscape
    • 6.9.4 Strategic outlook
    • 6.9.5 SWOT analysis
  • 6.10 Sanofi
    • 6.10.1 Business overview
    • 6.10.2 Financial data
    • 6.10.3 Therapy landscape
    • 6.10.4 Strategic outlook
    • 6.10.5 SWOT analysis
  • 6.11 Eisai Co., Ltd.
    • 6.11.1 Business overview
    • 6.11.2 Financial data
    • 6.11.3 Therapy landscape
    • 6.11.4 Strategic outlook
    • 6.11.5 SWOT analysis